Skip to main content
Top
Published in: Sleep and Breathing 1/2022

01-03-2022 | Sleep Apnea | Sleep Breathing Physiology and Disorders • Original Article

Use of average volume-assured pressure support as a therapeutic option in patients with central sleep apnea syndrome

Authors: John Mario Levri, Naomitsu Watanabe, Victor T. Peng, Steven M. Scharf, Montserrat Diaz-Abad

Published in: Sleep and Breathing | Issue 1/2022

Login to get access

Abstract

Purpose

Central sleep apnea (CSA) syndrome commonly occurs with other medical conditions such as congestive heart failure, opiate use, and brainstem disorders. Various treatment modalities have been used with varied effectiveness in an attempt to improve ventilation and reduce the apnea–hypopnea index (AHI) in patients with CSA. This study evaluated whether or not a bilevel positive airway pressure mode of noninvasive ventilation, average volume-assured pressure support (AVAPS) is effective in treating CSA.

Methods

This was a retrospective review of patients with CSA who underwent AVAPS titration studies at our institution. We included patients with CSA with apnea–hypopnea index (events/hour) (AHI) ≥ 15, and examined the effectiveness of AVAPS in reducing AHI, improving oxygenation parameters, and improving sleep architecture.

Results

There were 12 patients, with mean age 62.8 ± 11.5 years, body mass index (BMI) 33.5 ± 4.7 kg/m2, 8 men, and Epworth Sleepiness Scale 9.3 ± 4.9. Five patients had CSA attributed to opiate use, 4 patients had CSA with Cheyne-Stokes respiration, and 3 patients had primary CSA. The only significant change from baseline PSG was AHI reduction with AVAPS: 63.3 ± 19.1 to 30.5 ± 30.3 (p < 0.003). In 5 patients (42%), AHI was reduced to < 15 with AVAPS use. Improvement in AHI was not related to gender, BMI, opiate use, or age. Defining response to therapy as AHI reduced to < 15, we found that lack of hypertension was the only significant predictor of response (p = 0.045). No significant changes in sleep architecture between the two studies were found.

Conclusion

AVAPS is an effective mode of treating CSA in a significant proportion of patients. More studies are needed to confirm these findings and determine what factors are associated with response to therapy.
Literature
1.
go back to reference Berry, Richard, et al. (2014) Central sleep apnea syndromes. International Classification of Sleep Disorders, American Academy of Sleep Medicine, pp 69–107 Berry, Richard, et al. (2014) Central sleep apnea syndromes. International Classification of Sleep Disorders, American Academy of Sleep Medicine, pp 69–107
5.
go back to reference Magdy D, Metwally A. (2020) Effect of average volume-assured pressure support treatment on health-related quality of life in COPD patients with chronic respiratory failure: a randomized trial. Respir Res, pp 21–64 Magdy D, Metwally A. (2020) Effect of average volume-assured pressure support treatment on health-related quality of life in COPD patients with chronic respiratory failure: a randomized trial. Respir Res, pp 21–64
8.
go back to reference Johns M. About the ESS. Epworth Sleepiness Scale, epworthsleepinessscale.com/about-the-ess/ Johns M. About the ESS. Epworth Sleepiness Scale, epworthsleepinessscale.com/about-the-ess/
9.
go back to reference Berry R, Quan S, Abreu A, et al; for the American Academy of Sleep Medicine. 2020 The AASM manual for the scoring of sleep and associated events: rules, terminology, and technical specifications. Version 2.6. Darien, IL: American Academy of Sleep Medicine Berry R, Quan S, Abreu A, et al; for the American Academy of Sleep Medicine. 2020 The AASM manual for the scoring of sleep and associated events: rules, terminology, and technical specifications. Version 2.6. Darien, IL: American Academy of Sleep Medicine
Metadata
Title
Use of average volume-assured pressure support as a therapeutic option in patients with central sleep apnea syndrome
Authors
John Mario Levri
Naomitsu Watanabe
Victor T. Peng
Steven M. Scharf
Montserrat Diaz-Abad
Publication date
01-03-2022
Publisher
Springer International Publishing
Published in
Sleep and Breathing / Issue 1/2022
Print ISSN: 1520-9512
Electronic ISSN: 1522-1709
DOI
https://doi.org/10.1007/s11325-021-02379-z

Other articles of this Issue 1/2022

Sleep and Breathing 1/2022 Go to the issue

Sleep Breathing Physiology and Disorders • Original Article

Impact of the sleep apnea management group clinic on positive airway pressure adherence

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.